SEK 25.3
(1.61%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 2.14 Million SEK | -75.84% |
2022 | 8.87 Million SEK | -12.01% |
2021 | 10.08 Million SEK | 58.39% |
2020 | 6.36 Million SEK | -38.73% |
2019 | 10.39 Million SEK | 0.0% |
2018 | - SEK | 0.0% |
2017 | - SEK | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | 1.2 Million SEK | 0.0% |
2024 Q2 | 593 Thousand SEK | 0.0% |
2023 Q1 | 7.06 Million SEK | -20.43% |
2023 Q3 | 3.72 Million SEK | -31.95% |
2023 FY | 2.14 Million SEK | -75.84% |
2023 Q4 | 2.14 Million SEK | -42.47% |
2023 Q2 | 5.47 Million SEK | -22.44% |
2022 Q2 | 10.23 Million SEK | -12.76% |
2022 FY | 8.87 Million SEK | -12.01% |
2022 Q1 | 11.72 Million SEK | 16.29% |
2022 Q4 | 8.87 Million SEK | -7.03% |
2022 Q3 | 9.54 Million SEK | -6.7% |
2021 Q1 | 5.08 Million SEK | -20.19% |
2021 Q4 | 10.08 Million SEK | -19.79% |
2021 FY | 10.08 Million SEK | 58.39% |
2021 Q3 | 12.57 Million SEK | 120.75% |
2021 Q2 | 5.69 Million SEK | 12.08% |
2020 Q1 | 9.1 Million SEK | -12.41% |
2020 FY | 6.36 Million SEK | -38.73% |
2020 Q4 | 6.36 Million SEK | -2.85% |
2020 Q3 | 6.55 Million SEK | -15.98% |
2020 Q2 | 7.8 Million SEK | -14.29% |
2019 Q3 | 11.67 Million SEK | -9.81% |
2019 Q2 | 12.94 Million SEK | -8.87% |
2019 Q1 | 14.2 Million SEK | 0.0% |
2019 FY | 10.39 Million SEK | 0.0% |
2019 Q4 | 10.39 Million SEK | -10.96% |
2018 Q1 | - SEK | 0.0% |
2018 FY | - SEK | 0.0% |
2018 Q4 | - SEK | 0.0% |
2017 FY | - SEK | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Acarix AB (publ) | - SEK | -Infinity% |
ADDvise Group AB (publ) | 1.45 Billion SEK | 99.853% |
ADDvise Group AB (publ) | 1.45 Billion SEK | 99.853% |
Arcoma AB | 1.92 Million SEK | -11.261% |
Bactiguard Holding AB (publ) | 42.3 Million SEK | 94.932% |
BICO Group AB (publ) | 1.75 Billion SEK | 99.878% |
Boule Diagnostics AB (publ) | 57.7 Million SEK | 96.284% |
CellaVision AB (publ) | 28.66 Million SEK | 92.52% |
Clinical Laserthermia Systems AB (publ) | 223 Thousand SEK | -861.435% |
Chordate Medical Holding AB (publ) | - SEK | -Infinity% |
C-Rad AB (publ) | 1.75 Million SEK | -22.305% |
Duearity AB (publ) | 2.94 Million SEK | 27.075% |
Dignitana AB (publ) | 6.07 Million SEK | 64.719% |
Episurf Medical AB (publ) | 2.3 Million SEK | 6.783% |
Getinge AB (publ) | 3.9 Billion SEK | 99.945% |
Scandinavian Real Heart AB (Publ) | 6.35 Million SEK | 66.252% |
Iconovo AB (publ) | 4.9 Million SEK | 56.306% |
Integrum AB (publ) | 4.84 Million SEK | 55.744% |
Luxbright AB (publ) | 206.02 Thousand SEK | -940.655% |
OssDsign AB (publ) | 214 Thousand SEK | -901.869% |
Paxman AB (publ) | 2.53 Million SEK | 15.324% |
Promimic AB (publ) | - SEK | -Infinity% |
Qlife Holding AB (publ) | 3 Million SEK | 28.628% |
SciBase Holding AB (publ) | 4.17 Million SEK | 48.696% |
ScandiDos AB (publ) | - SEK | -Infinity% |
Sectra AB (publ) | 19.2 Million SEK | 88.836% |
Sedana Medical AB (publ) | 1.01 Million SEK | -111.858% |
Senzime AB (publ) | 8.57 Million SEK | 75.006% |
SpectraCure AB (publ) | 4.39 Million SEK | 51.239% |
Stille AB | 38.06 Million SEK | 94.368% |
Vitrolife AB (publ) | 1.87 Billion SEK | 99.886% |
Xvivo Perfusion AB (publ) | 21.16 Million SEK | 89.872% |